Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Stopped early · Phase 2

Conditions studied: Schizophrenia

In brief

This is a study of ABT-126 in the treatment of cognitive impairment associated with schizophrenia (CIAS), a long-term extension study to study M10-855 (NCT01655680).

Key facts

Study ID

NCT01834638

Run by

AbbVie

People needed

268

Starts

2013-03-01

Expected to finish

2014-11-01

Last updated by the study team

2018-05-02

Who can join

Age: 20 and older, up to 66. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject was randomized into Study M10-855 and completed through Week 26 in that study.
• The subject is receiving one or more antipsychotic medications.

You may not qualify if…

• Additional history collected during participation in Study M10-855 provides evidence that, in the investigator's judgement, the subject does not have schizophrenia.
• The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile, and/or electrocardiogram (ECG) measurements in Study M10-855 that indicates the subject is likely to become medically unstable during the current study.
• The subject is currently taking or is expected to be prescribed any excluded medication without the approval of AbbVie medical monitor.
• The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.

Where it is running

• Site Reference ID/Investigator# 95381 — Costa Mesa, California, United States
• Site Reference ID/Investigator# 95400 — Escondido, California, United States
• Site Reference ID/Investigator# 95406 — Garden Grove, California, United States
• Site Reference ID/Investigator# 95378 — National City, California, United States
• Site Reference ID/Investigator# 95390 — Norwalk, California, United States
• Site Reference ID/Investigator# 95386 — Oakland, California, United States
• Site Reference ID/Investigator# 95391 — Oceanside, California, United States
• Site Reference ID/Investigator# 95380 — Orange, California, United States
• Site Reference ID/Investigator# 95395 — Pico Rivera, California, United States
• Site Reference ID/Investigator# 95403 — Riverside, California, United States
• Site Reference ID/Investigator# 128356 — San Bernardino, California, United States
• Site Reference ID/Investigator# 95405 — San Diego, California, United States
• Site Reference ID/Investigator# 95397 — San Diego, California, United States
• Site Reference ID/Investigator# 95384 — San Gabriel, California, United States
• Site Reference ID/Investigator# 95385 — Santa Ana, California, United States
• Site Reference ID/Investigator# 95387 — Torrance, California, United States
• Site Reference ID/Investigator# 95382 — New Haven, Connecticut, United States
• Site Reference ID/Investigator# 95399 — Atlanta, Georgia, United States
• Site Reference ID/Investigator# 95377 — Marietta, Georgia, United States
• Site Reference ID/Investigator# 120595 — Chicago, Illinois, United States
• Site Reference ID/Investigator# 129380 — Hoffman Estates, Illinois, United States
• Site Reference ID/Investigator# 95379 — Cedarhurst, New York, United States
• Site Reference ID/Investigator# 95392 — Rochester, New York, United States
• Site Reference ID/Investigator# 95388 — Philadelphia, Pennsylvania, United States
• Site Reference ID/Investigator# 95398 — Chino, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.